Risk stratification using the Merlin Assay (CP-GEP) in an independent cohort of 930 patients with clinical stage I/II melanoma who did not undergo sentinel lymph node biopsy.

Date publication

mai 2025

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Dr AMARAL Teresa Maria

Tous les auteurs :
Amaral T, Chatziioannou E, Nuebling A, Nanz L, Sinnberg T, Niessner H, Arentsen T, Ruiter R, Dwarkasing J, Eggermont AM, Leiter U, Flatz L, Forchhammer S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40274320

Résumé

More than 80 % of patients with melanoma are diagnosed without nodal metastasis, but most of those who relapse or die from melanoma are initially diagnosed as low risk early-stage. Here we investigate the ability of the Merlin Assay to stratify patients who did not undergo sentinel lymph node biopsy (SLNB) for their risk of recurrence.

Mots clés

CP-GEP, Cutaneous melanoma, Gene expression profile, Melanoma specific survival, Personalized therapy, Prognostic factors, Relapse-free survival, SLNB, Stage I/II

Référence

Eur J Cancer. 2025 05 2;220:115372